IXICO specialises in PD imaging, providing advanced imaging biomarkers to quantify essential PD measurements such as dopamine transporter (DaT) density and brain atrophy for the assessment of drug safety, eligibility and efficacy.
IXICO has supported numerous brain scans collected through a variety of PD research initiatives, promoting innovation and harmonising imaging data for better clinical trial outcomes. The IXI™ platform improves the accuracy and efficiency of volumetric measurements with PD-specific services: extensive imaging support with global site management, centralised radiology reads, PD-specific workflows, and advanced bespoke image analytics.
Work with leading institutions and initiatives, for example, C-Path CPP and tracer manufacturers such as GE, underline IXICO’s expertise, ensures successful outcomes and contributes to IXICO’s position as a dependable partner helping to advance PD research and clinical trials.
Including DaTSPECT, to assess dopamine transporter density in the brain, aiding in patient selection and trial eligibility.
Supporting various tracers to measure dopaminergic function and neuroinflammation.
Amyloid PET
Tau PET
Structural MRI, Vascular pathology
Quantitative Susceptibility Mapping (QSM)
Diffusion MRI
Arterial Spin Labelling (ASL) MRI
Resting State fMRI (rs-fMRI)
Free Water imaging
White matter changes
Neuromelanin
Neuroinflammation
Emerging as a relevant measure (pigment found in dopamine neurons) for PD research in PD clinical trials which requires expert understanding of the practical and technical challenges in NM imaging, such as low spatial resolution and long acquisition times.
In addition to Parkinson’s Disease, IXICO also specialises in imaging in other Parkinsonian disorders, such as Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA).
Imaging features can help differentiate PSP and MSA from Parkinson's disease, with distinct visually identifiable features, such as in PSP, where midbrain atrophy results in the Hummingbird appearance on axial T1 MRI images. Such features are identified by our team of expert neuroradiology readers during control centralised eligibility reads.
Volumetric MRI analysis can be used for quantitative assessment of regional atrophy, as well as functional PET and SPECT imaging, playing a role in the assessment of reduced dopamine transporter binding.